Last reviewed · How we verify
Ranibizumab Injection
Ranibizumab Injection is a Small molecule drug developed by University of Giessen. It is currently FDA-approved. Also known as: Lucentis, Dexamethasone Implant, Aflibercept, Laser, Panretinal photocoagulation.
Ranibizumab injection is a vascular endothelial growth factor A inhibitor used to treat conditions such as macular degeneration, macular edema, and diabetic macular edema. It is a monoclonal antibody that works by inhibiting the action of vascular endothelial growth factor A, a protein involved in the formation of new blood vessels.
At a glance
| Generic name | Ranibizumab Injection |
|---|---|
| Also known as | Lucentis, Dexamethasone Implant, Aflibercept, Laser, Panretinal photocoagulation |
| Sponsor | University of Giessen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (PHASE3)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (PHASE3)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranibizumab Injection CI brief — competitive landscape report
- Ranibizumab Injection updates RSS · CI watch RSS
- University of Giessen portfolio CI
Frequently asked questions about Ranibizumab Injection
What is Ranibizumab Injection?
Who makes Ranibizumab Injection?
Is Ranibizumab Injection also known as anything else?
What development phase is Ranibizumab Injection in?
Related
- Manufacturer: University of Giessen — full pipeline
- Also known as: Lucentis, Dexamethasone Implant, Aflibercept, Laser, Panretinal photocoagulation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing